Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their clinical programs. They emphasized the importance of their research and development efforts.
Management expressed confidence in their ongoing clinical trials.
They highlighted the potential of their pipeline products.
Despite missing on EPS, Kodiak Sciences saw a positive stock reaction, rising nearly 10%. Investors may be encouraged by management's focus on clinical trials and product pipeline, indicating potential future growth. The lack of revenue data and guidance suggests uncertainty, but the stock's increase reflects optimism in the company's direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MACOM TECHNOLOGY SOL
Nov 13, 2018